How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?
- 9 December 2022
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (2) , 229-240
Abstract
Introduction: Non‐parallelism in factor assays can lead to incorrect factor activities. Parallelism can be assessed by calculating the coefficient of variation (CV) of results obtained on 3 dilutions of the same sample. Some authors have proposed that if there is 25 IU/dl (plus no interfering substances) all CVs were < 15%. One sample (low factor activities 10–15 IU/dl), had CVs > 15% in FII, FVII and FXII assays only. SR outside of 0.9–1.1 were seen in FII and FXII assays at different levels of clotting factor including some within the normal range. Non‐parallelism was detected more frequently with SR than CV for those with interfering substances.Conclusions: SR outside of 0.9–1.1 were seen in different levels of clotting factors, including samples which did not contain interfering substances. The target of 15% CV was a better discriminator than a SR for acceptance. When factor levels were reduced to around 10–15 IU/dl, a target 20 %CV was more appropriate than 15%. It might be appropriate for laboratories to assess locally whether their acceptance criteria need to be wider at low levels of clotting factors.Keywords
This publication has 31 references indexed in Scilit:
- The Effect of Dabigatran on Select Specialty Coagulation AssaysAmerican Journal of Clinical Pathology, 2013
- Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literatureThrombosis Research, 2012
- Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxabanThrombosis Research, 2012
- Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assaysThrombosis and Haemostasis, 2011
- Measurement of factor VIII activity using one‐stage clotting assay: a calibration curve has not to be systematically included in each runHaemophilia, 2010
- Avoiding errors in the laboratory evaluation of potent lupus anticoagulantsAmerican Journal of Hematology, 2010
- Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitorsThrombosis and Haemostasis, 2010
- Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunctionBlood Coagulation & Fibrinolysis, 2008
- The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' OrganisationHaemophilia, 2004
- Blood-Coagulation Factor VIII: Genetics, Physiological Control, and Bioassay1966